Skip to Main Content

Paper Details

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Clin Cancer Res
2
2023
89Zr, CDKN2A/B, ERBB2, HER2, HER2-expressing tumor, HER2-expressing tumor clones, MSK, MSMB, MT1E, MT1H, MT2A, MYC, Metastatic Esophagogastric Cancer, PD-1, PTC, Single, ctDNA, esophagogastric cancer, metastatic esophagogastric cancer, patients, pembrolizumab, plasma circulating tumor DNA, scRNA, trastuzumab, tumor-matched ctDNA
Author NameAffiliation
Walid K ChatilaTri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College
Richard K G DoMemorial Sloan Kettering Cancer Center
Neeta Pandit-TaskarMemorial Sloan Kettering Cancer Center
Umesh BhanotMemorial Sloan Kettering Cancer Center
Umesh BhanotMemorial Sloan Kettering Cancer Center
Rebecca NagyInc.
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine
Nikolaus SchultzMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
  • 1 - 11

Datasets

Release 1.2